Press Release



MACU

VADODAR

Profit before Tax up 24% to Rs 352 crores for the quarter Net Profit up 25% to Rs 293 crores

Vadodara, January 19th, 2021

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st December 2020.

Financial Highlights

- Net Sales for the quarter up 9% to Rs 1314 crores from Rs. 1209 crores.
- Net Profit for the quarter up 25% to Rs 293 crores from Rs 234 crores.
- Net sales for 9M FY21 up 21% to Rs 4113 crores against Rs 3399 crores.
- Net profit for 9M FY21 up 53% to Rs 927 crores from Rs 604 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in current quarter,"

Operational Highlights

International Business

- International formulations grew 3% to Rs 683 crores in the quarter and 27% to Rs 2233 crores for 9M FY21.
- Ex-US International Formulations grew 14% to Rs 171 crores in the quarter and 49% to Rs 544 Crores for 9M FY21.
- 8 ANDA approvals received during the quarter; 137 Cumulative ANDA approvals.

India Formulations Business

- India formulations business grew 14% to Rs 418 crores in the quarter and 5% to Rs 1138 crores for 9M FY21.
- Specialty segments grew by 16% for the quarter led by Cardio, Diabeto,
 Gyanaec and Gastro Segments

API Business

- API business grew 21% to Rs 214 crores in the quarter and 34% to Rs 741 crores for 9M FY21.
- 4 DMF were filed in the quarter, Cumulative DMF fillings at 115.



Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY21	Q3 FY20	% Change	9M FY21	9M FY20	% Change
Formulation						
USA	512	515	-1%	1689	1399	21%
Ex- US	171	149	14%	544	364	49%
India	418	368	14%	1138	1083	5%
API	214	177	21%	741	553	34%
Total	1314	1209	9%	4113	3399	21%

Summary of Profit is as under:

(Rs in Crores)

Particulars	Q3 FY21	Q3 FY20	% Change	9M FY21	9 M FY20	% Change
EBITDA Pre R&D	536	466	15%	1713	1335	28%
EBITDA Pre R&D %	41%	39%		42%	39%	
EBITDA Post R&D	401	332	21%	1272	907	40%
EBITDA Post R&D %	31%	27%		31%	27%	
Profit Before Tax	352	283	24%	1126	741	52%
Net Profit after Tax	293	234	25%	927	604	53%



ALEMBIC PHARMACEUTICALS LIMITED



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Mitanshu Shah

Phone: +91 22 – 306 11681 Phone: +91 265 – 3007630

Email: ajay.desai@alembic.co.in Email: mitanshu.shah@alembic.co.in

